Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31262807 | 1.00 | BCL2L1 (0.54) | BCL2L1GPR35CHRNA7PTPN2PPARA | |
| SCHEMBL153428 | 0.87 | BCL2L1 (0.54) | BCL2L1GPR35CHRNA7PTPN2PPARA | |
| SCHEMBL147472 | 0.85 | CHRNA7 (0.48) | BCL2L1CHRNA7PPARADYRK1ACES2 | |
| SCHEMBL30456961 | 0.85 | DYRK1A (0.50) | CHRNA7PTPN2PPARAKDM4EALDH1A1 | |
| SCHEMBL4654119 | 0.84 | HDAC1 (0.52) | CHRNA7PTPN2PPARAKDM4EALDH1A1 | |
| SCHEMBL3580021 | 0.84 | BCL2L1 (0.49) | BCL2L1GPR35CHRNA7PTPN2DYRK1A | |
| SCHEMBL3573988 | 0.82 | BCL2L1 (0.46) | BCL2L1GPR35CHRNA7PTPN2PPARA | |
| SCHEMBL3562083 | 0.80 | BCL2L1 (0.51) | BCL2L1GPR35CHRNA7PTPN2TBXAS1 | |
| Isopropylamine SCHEMBL13735900 | 0.79 | BCL2L1 (0.46) | BCL2L1GPR35CHRNA7PTPN2PPARA | |
| SCHEMBL15697513 | 0.79 | PPARA (0.57) | PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | claimed |
| US-9232792-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-01-12 | — | — | US | claimed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | claimed |
| EP-2926660-A1 | METHOD FOR PROMOTING PLANT GROWTH | Sumitomo Chemical Company Limited (JP) | 2015-10-07 | — | — | EP | claimed |
| EP-2706850-A1 | METHOD FOR PROMOTING PLANT GROWTH | Sumitomo Chemical Company, Limited (JP) | 2014-03-19 | — | — | EP | claimed |
| US-20140031233-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-30 | — | — | US | claimed |
| WO-2012153861-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-15 | — | — | WO | claimed |
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| US-12583849-B2 | KCNT1 inhibitors and methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| EP-4692069-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4110317-B1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| WO-2005077926-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005070885-A1 | BIS BICYCLIC AMIDES AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165046-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | KCNT1, SCN1A, KCNT2 | BCL2L1 1359/4885GPR35 2308/4885CHRNA7 132/4885 |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | BCL2L1 2656/4885GPR35 648/4885CHRNA7 255/4885 |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | BCL2L1 632/4885GPR35 55/4885CHRNA7 418/4885 |
| US-20050165046-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | BCL2L1 753/4885GPR35 40/4885CHRNA7 377/4885 |
| US-20140031233-A1 | METHOD FOR PROMOTING PLANT GROWTH | MYB, GRHPR, HACL2 | BCL2L1 1455/4885GPR35 4429/4885CHRNA7 4600/4885 |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | FGF2, BROX, BOLA2; BOLA2B | BCL2L1 2137/4885GPR35 3997/4885CHRNA7 4781/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | BCL2L1 3789/4885GPR35 60/4885CHRNA7 1077/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | BCL2L1 2632/4885GPR35 674/4885CHRNA7 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.